Ab&B Bio-Tech CO., LTD. JS Class H stock analysis
Want to see HK:2627 full AI Analyst Report?
Ab&B Bio-Tech CO., LTD. JS Class H (2627) Stock Price & Analysis
2627 Stock Chart & Stats
- Day’s Range
- HKD 28.88 - HKD 30.46
- 52-Week Range
- HKD 28.88 - HKD 73.00
- Previous Close
- HKD 29.32
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- HKD 11.54B
- Enterprise Value
- HKD 9927.78T
- Total Cash (Recent Filing)
- HKD 108.36M
- Total Debt (Recent Filing)
- HKD 931.93M
- Price to Earnings (P/E)
- ―
- Beta
- 1.32
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Strong 2024 Revenue Rebound And Gross Margin Recovery
A large revenue rebound coupled with a dramatic gross margin swing indicates the business achieved meaningful pricing, mix or cost improvements. These changes improve the path to durable operating leverage and reduce the scale of revenue needed to reach sustainable profitability over the next several quarters.
Positive Equity Buffer On The Balance Sheet
Maintaining positive equity gives the company a capital cushion that reduces immediate insolvency risk and supports continued operations or negotiations with creditors. This structural buffer preserves strategic optionality for refinancing, partnerships, or asset-backed funding over 2–6 months.
Operating In Specialty & Generic Pharmaceuticals
Participation in the specialty & generic drugs sector offers durable demand drivers and product differentiation opportunities. Regulatory and manufacturing barriers in this industry can create sustainable competitive advantages for proven products, supporting longer-term revenue visibility and strategic partnerships.
Bears Say
Persistent Unprofitable Operations And Material Cash Burn
Ongoing operating losses and structural cash burn impair the company’s ability to self-fund growth or R&D. Without sustained margin expansion, the firm will remain dependent on external financing, increasing dilution risk and reducing strategic flexibility over the coming months.
Very Weak Cash Generation And Negative Free Cash Flow
Large negative operating and free cash flows indicate operations are not generating internal funding for capex or commercialization. This structural cash shortfall forces ongoing reliance on debt or equity raises, constraining long-term reinvestment and raising execution risk.
Elevated Leverage And Rising Debt Load
A very high debt-to-equity ratio and a sharp rise in debt reduce financial flexibility and elevate interest and covenant risk. With continued losses, leverage amplifies downside, limits strategic options, and increases the probability of distress or restrictive financing terms over the medium term.
Ab&B Bio-Tech CO., LTD. JS Class H News
2627 FAQ
What was Ab&B Bio-Tech CO., LTD. JS Class H’s price range in the past 12 months?
What is Ab&B Bio-Tech CO., LTD. JS Class H’s market cap?
When is Ab&B Bio-Tech CO., LTD. JS Class H’s upcoming earnings report date?
How were Ab&B Bio-Tech CO., LTD. JS Class H’s earnings last quarter?
Is Ab&B Bio-Tech CO., LTD. JS Class H overvalued?
Does Ab&B Bio-Tech CO., LTD. JS Class H pay dividends?
What is Ab&B Bio-Tech CO., LTD. JS Class H’s EPS estimate?
How many shares outstanding does Ab&B Bio-Tech CO., LTD. JS Class H have?
What happened to Ab&B Bio-Tech CO., LTD. JS Class H’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Ab&B Bio-Tech CO., LTD. JS Class H?
What is the TipRanks Smart Score and how is it calculated?
Ab&B Bio-Tech CO., LTD. JS Class H Stock Smart Score
Company Description
Ab&B Bio-Tech CO., LTD. JS Class H
Ab&B Bio-Tech Co., Ltd. engages in the research, development, manufacturing and commercialization of innovative and traditional vaccines. Its products include quadrivalent subunit influenza and lyophilized human rabies vaccines. The company was founded by You Cai An on October 28, 2015 and is headquartered in Taizhou, China.
- Sector
- General
- Industry
- Biotechnology
- CEO
- You Cai An
- Employees
- 583
- Website
- www.abbbio.com
- Address
- No. 32 Xinglin Road, Taizhou, 225300, CN
Ab&B Bio-Tech CO., LTD. JS Class H (2627) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 3 | 4 | 13 |
| Technical Analysis | 2 | 4 | 2 |
| Moving Averages | 1 | 0 | 11 |









